



# GLOBAL HOSPITAL

॥ सर्वे सन्तु निरामयाः ॥

A division of  
Global Longlife Hospital & Research Ltd.

Letter No.: GLHRL/33/2023-24

Date: November 11, 2023

To,  
Listing Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

SCRIPT CODE: 543520

ISIN: INE0J2K01014

**Subject: Outcome of Meeting of Board of Directors held today i.e. Saturday, November 11, 2023, in terms of Regulation 30 of SEBI (LODR) Regulations, 2015, for consideration and approval of Unaudited Financial Results for the Half Year ended on September 30, 2023.**

Dear Sir/Madam,

In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that in the Board Meeting held today (i.e. Saturday, November 11, 2023), the Board of Directors of the Company has considered and approved the Unaudited Financial Results for the Half Year ended September 30, 2023 along with the Limited Review Report.

The above matter has been duly approved by the Board of Directors at their meeting which commenced at 12:30 P.M. and concluded at 04:30 P.M.

In this connection, we are enclosing herewith Unaudited Financial Results for the Half year ended on September 30, 2023 and Limited Review Report.

The same will be made available on the Company's website [www.globalhospital.co.in](http://www.globalhospital.co.in).

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

  
Dhruv Jani  
Managing Director  
DIN: 03154680

Encl: a/a



**LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY STANDALONE FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**To the Board of Directors of  
Global Longlife Hospital and Research Limited**


We have reviewed the accompanying statement of unaudited financial results of **Global Longlife Hospital and Research Limited** for the period ended 30<sup>th</sup> September, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For, KARMA & Co. LLP  
Chartered Accountants  
FRN No. 127544W/W100376**

**Place: Ahmedabad  
Date: 11<sup>th</sup> November, 2023**



  
**CA Jignesh A. Dhaduk  
Designated Partner  
M.No.129149  
UDIN: 23129149BGVLMG2072**

**GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED**  
CIN: L85110GJ2012PLC068700

Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad - 380054

**UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30.09.2023**

(Rs. in Lakhs except per share data)

Sr. No.	Particulars	Half Year Ended			Year Ended	
		30.09.2023	31.03.2023	30.09.2022	31.03.2023	31.03.2022
		Unaudited	Audited	Unaudited	Audited	Audited
	Revenue from Operations	1,233.00	1,170.22	1,179.95	2,350.17	3,281.54
	Other Income	2.10	17.06	6.81	23.87	22.79
1	<b>Total Income</b>	<b>1,235.09</b>	<b>1,187.27</b>	<b>1,186.77</b>	<b>2,374.04</b>	<b>3,304.33</b>
2	<b>Expenses</b>					
	Direct Expenses	567.58	389.26	525.76	915.02	1,364.18
	Purchase of Stock-in-Trade	83.59	372.72	53.73	426.45	367.51
	Changes in inventories of finished goods and stock in trade	(47.88)	(47.62)	54.35	6.73	(7.06)
	Employee benefits expenses	215.29	181.40	181.61	363.02	406.06
	Finance Costs	40.51	19.64	20.41	40.05	139.89
	Depreciation and amortisation expenses	61.49	58.97	57.68	116.65	114.37
	Other Expenses	143.56	48.51	186.84	235.35	348.37
	<b>Total Expenses</b>	<b>1,064.14</b>	<b>1,022.89</b>	<b>1,080.38</b>	<b>2,103.27</b>	<b>2,733.32</b>
3	<b>Profit/(Loss) before exceptional and extraordinary items and tax (1 - 2)</b>	<b>170.96</b>	<b>164.39</b>	<b>106.39</b>	<b>270.78</b>	<b>571.01</b>
4	Exceptional Items	-	-	-	-	-
5	<b>Profit/(Loss) before extraordinary item and tax (3 - 4)</b>	<b>170.96</b>	<b>164.39</b>	<b>106.39</b>	<b>270.78</b>	<b>571.01</b>
6	Extraordinary Items	-	-	-	-	-
7	<b>Profit/(Loss) before tax (5 - 6)</b>	<b>170.96</b>	<b>164.39</b>	<b>106.39</b>	<b>270.78</b>	<b>571.01</b>
8	<b>Tax Expense</b>					
	a) Current tax	28.54	27.44	17.76	45.20	95.30
	b) Deferred tax	39.48	29.94	12.80	42.73	118.32
	c) Excess/(Short) Provision Of Earlier Years	-	0.10	-	0.10	-
9	<b>Net Profit/(Loss) from continuing activities after tax (7 - 8)</b>	<b>102.94</b>	<b>106.91</b>	<b>75.84</b>	<b>182.75</b>	<b>357.39</b>
10	Net Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-	-
12	<b>Net Profit/(Loss) from discontinued operations after tax (10-11)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
13	<b>Net Profit/(Loss) for the period after tax (9 + 12)</b>	<b>102.94</b>	<b>106.91</b>	<b>75.84</b>	<b>182.75</b>	<b>357.39</b>
14	<b>Other Comprehensive Income, net of tax (OCI)</b>					
	a) Items that will not be reclassified to profit or loss	-	-	-	-	-
	b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	<b>Total</b>					
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>102.94</b>	<b>106.91</b>	<b>75.84</b>	<b>182.75</b>	<b>357.39</b>
16	<b>Details of Equity Share Capital</b>					





# GLOBAL HOSPITAL

॥ सर्वे सन्तु निरामयाः ॥

A division of

Global Longlife Hospital & Research Ltd.

	Paid-up Equity Share Capital	1,050.00	1,050.00	1,050.00	1,050.00	700.00
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
17	Reserves excluding revaluation reserves	-	-	-	5,378.97	996.22
18	Basic earning (loss) per share from continuing and discontinued operation	0.98	1.05	0.74	1.79	5.11
19	Diluted earning (loss) per share from continuing and discontinued operation	0.98	1.05	0.74	1.79	5.11
	Debt Equity Ratio	0.17	0.14	0.08	0.14	0.17
	Debt Service Coverage Ratio	27.55	667.08	4.80	0.40	3.01
	Interest Service Coverage Ratio	55.72	667.08	24.76	54.51	8.32

For Global Longlife Hospital and Research Limited



Dhruv Jani  
Managing Director  
DIN: 03154680

Notes:

Date: 11.11.2023  
Place: Ahmedabad

- 1) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on November 11, 2023.
- 2) The company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under AS - 17 Segment Reporting.
- 3) Previous period figures have been re-grouped / re-classified wherever necessary.
- 4) As the company is listed on SME Platform of BSE Limited, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015.
- 5) The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act, 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.
- 6) The company has received an order on October 21, 2023 which was passed on October 18, 2023 from the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad bench regarding our case number C.P.(IB)/1(AHM)2023 between Rajesh Kashiram Agrawal (applicant) V/s Global Longlife Hospital and Research Pvt Ltd. (Respondent) which is disposed off (as being settled out of court).
- 7) The results for the half year and year ended September 30, 2023 are available on the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)) and also on the company's website (URL: [www.globalhospital.co.in](http://www.globalhospital.co.in))
- 8) As the company do not have any Holding/Subsidiary/Joint Venture/Associate concern, no reporting has been made in this regards.



# GLOBAL HOSPITAL


A division of  
Global Longlife Hospital & Research Ltd.

॥ सर्वे सन्तु निरामयाः ॥

## STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lakhs)

	Particulars	As At 30.09.2023	As At 31.03.2023
		Unaudited	Audited
	<b>Equity and liabilities</b>		
<b>1</b>	<b>Shareholders' funds</b>		
	Share capital	1,050.00	1,050.00
	Reserves and surplus	5,481.91	5,378.97
	Money received against share warrants		-
	<b>Total shareholders' funds</b>	<b>6,531.91</b>	<b>6,428.97</b>
<b>2</b>	Share application money pending allotment	-	-
<b>3</b>	Deferred government grants	-	-
<b>4</b>	Minority interest	-	-
<b>5</b>	<b>Non-Current Liabilities</b>		
	Long-term borrowings	138.88	364.23
	Deferred tax liabilities (net)	-	-
	Foreign currency monetary item translation difference liability account	-	-
	Other long-term liabilities	8.11	8.64
	Long-term provisions	8.54	8.01
	<b>Total Non-Current Liabilities</b>	<b>155.53</b>	<b>380.88</b>
<b>6</b>	<b>Current Liabilities</b>		
	Short-term borrowings	991.60	565.26
	Trade Payables		
	(A) Total outstanding dues of micro enterprises and small enterprises.	28.07	59.30
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises.	62.45	71.79
	Other current liabilities	44.16	40.21
	Short-term provisions	30.76	47.42
	<b>Total current liabilities</b>	<b>1,157.04</b>	<b>783.98</b>
	<b>Total equity and liabilities</b>	<b>7,844.47</b>	<b>7,593.83</b>
	<b>Assets</b>		
<b>1</b>	<b>Non-current assets</b>		





# GLOBAL HOSPITAL

॥ सर्वे सन्तु निरामयाः ॥

A division of

Global Longlife Hospital & Research Ltd.

(i)	<b>Fixed assets</b>		
	Tangible assets	1,759.46	1,651.50
	Producing properties	-	-
	Intangible assets	0.59	0.62
	Preproducing properties	-	-
	Tangible assets capital work-in-progress	-	102.99
	Intangible assets under development or work-in-progress	-	-
	<b>Total fixed assets</b>	<b>1,760.05</b>	<b>1,755.11</b>
(ii)	Non-current investments	10.00	10.00
(iii)	Deferred tax assets (net)	174.99	214.47
(iv)	Foreign currency monetary item translation difference asset account	-	-
(v)	Long-term loans and advances	-	-
(vi)	Other non-current assets	2,222.23	2,261.44
	<b>Total non-current assets</b>	<b>2,407.22</b>	<b>2,485.91</b>
<b>2</b>	<b>Current assets</b>		
	Current investments	-	-
	Inventories	129.42	81.54
	Trade receivables	1,259.63	969.70
	Cash and cash equivalents	311.84	360.15
	Short-term loans and advances	162.59	143.27
	Other current assets	1,813.72	1,798.15
	<b>Total current assets</b>	<b>3,677.20</b>	<b>3,352.81</b>
	<b>Total assets</b>	<b>7,844.47</b>	<b>7,593.83</b>

For Global Longlife Hospital and Research Limited

  
BODAKDEV  
AHMEDABAD

**Dhruv Jani**  
Managing Director  
DIN: 03154680

Date: 11.11.2023

Place: Ahmedabad



# GLOBAL HOSPITAL

A division of  
Global Longlife Hospital & Research Ltd.

॥ सर्वे सन्तु निरामयाः ॥

## CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30.09.2023

(Rs. In Lakhs)

	Particulars	30-09-2023 Unaudited	30-09-2022 Unaudited	31-03-2023 Audited
<b>A.</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
	Net Profit before taxation and extraordinary items	170.96	106.39	270.78
	<b>Adjustment for :-</b>			
	Depreciation and Amortization	61.49	57.68	116.65
	Non-cash items	-		57.58
	Interest Income		(5.08)	
	Loss on sale of asset	5.83		
	Dividend income		(1.50)	
	Finance Costs	40.51	20.41	40.05
		278.79	177.89	485.05
	<b>Operating Profit before working capital changes</b>			
	<b>Change in working Capital :</b>			
	<b>Adjustment for Decrease (Increase) in operating assets</b>			
	Inventories	(47.88)	54.35	6.73
	Trade receivables	(289.93)	(307.33)	(78.98)
	Other Assets	26.42	(92.89)	(3,768.51)
	<b>Adjustment for (Decrease) Increase in operating liabilities</b>			
	Trade payables	(40.56)	(348.17)	(296.77)
	Other current liabilities	3.41	(198.52)	(225.14)
	Other Provision	0.52	(34.51)	(24.28)
	Short Term Loans & Advances		111.43	
	<b>Cash Generated from Operations</b>			
	Direct tax Paid	(61.83)	80.44	127.00
	Dividends received	(1.50)		(3.00)
	Interest received	(0.27)		(9.62)
	Income tax refund received			
	Cash Flow before extraordinary items			
	Extraordinary Items/Prior Period Items			
	<b>Net cash from Operating Activities</b>	<b>(132.83)</b>	<b>(718.19)</b>	<b>(4,041.52)</b>
<b>B.</b>	<b>NET CASH FLOW FROM INVESTMENT ACTIVITIES</b>			
	Purchase of Fixed Assets			
	Purchase of Property, Plant and Equipment	(78.11)	(6.18)	
	Investment in Term Deposits	(2.54)	(25.36)	(1.82)
	Proceeds from sales of property, plant and equipment	5.83		
	Purchase of property, plant and equipment		(2,900.15)	(200.44)
	Dividends received	1.50	1.50	3.00
	Interest received	0.62		9.18



# GLOBAL HOSPITAL

A division of  
Global Longlife Hospital & Research Ltd.

॥ सर्वे सन्तु निरामयाः ॥

	Loans and Advances given	(3.28)		
	Interest income		5.08	
	Proceeds from sale of fixed assets			
	<b>Net Cash from Investment Activities</b>	<b>(75.97)</b>	<b>(2,925.11)</b>	<b>(190.08)</b>
<b>C.</b>	<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
	Repayment of Long Term Borrowings			
	Proceeds from Long Term Borrowings	(225.34)		
	Proceeds from issuing shares	-	4,900.00	4,550.00
	Proceeds from borrowings	426.35		82.11
	Repayments of borrowings		(336.19)	(22.14)
	Dividends paid			
	Interest paid	(40.51)	(20.41)	(40.05)
	<b>Net Cash from financial activities</b>	<b>160.49</b>	<b>4,543.41</b>	<b>4,569.91</b>
	<b>NET INCREASE /(-) DECREASE IN CASH AND CASH EQUIVALENTS</b>	<b>(48.31)</b>	<b>900.11</b>	<b>338.32</b>
	<b>OPENING BALANCE IN CASH AND CASH EQUIVALENTS</b>	<b>360.15</b>	<b>21.83</b>	<b>21.83</b>
	<b>CLOSING BALANCE IN CASH AND CASH EQUIVALENTS</b>	<b>311.84</b>	<b>921.94</b>	<b>360.15</b>

For Global Longlife Hospital and Research Limited

  
Dhruv Jani  
Managing Director  
DIN: 03154680

Date: 11.11.2023  
Place: Ahmedabad